CD36 inhibitors reduce postprandial hypertriglyceridemia and protect against diabetic dyslipidemia and atherosclerosis.
CD36 is recognized as a lipid and fatty acid receptor and plays an important role in the metabolic syndrome and associated cardiac events. The pleiotropic activity and the multiple molecular associations of this scavenger receptor with membrane associated molecules in different cells and tissues hav...
Guardado en:
Autores principales: | Alain Geloen, Lionel Helin, Benjamine Geeraert, Eric Malaud, Paul Holvoet, Gerard Marguerie |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2012
|
Materias: | |
Acceso en línea: | https://doaj.org/article/4639332cd7ca4104a34711ed04f4f491 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Endothelial Cell CD36 Reduces Atherosclerosis and Controls Systemic Metabolism
por: Umar R. Rekhi, et al.
Publicado: (2021) -
Hypertriglyceridemia influences the degree of postprandial lipemic response in patients with metabolic syndrome and coronary artery disease: from the CORDIOPREV study.
por: Juan F Alcala-Diaz, et al.
Publicado: (2014) -
ABCC6 deficiency promotes dyslipidemia and atherosclerosis
por: Christopher Brampton, et al.
Publicado: (2021) -
PPAR agonist-induced reduction of Mcp1 in atherosclerotic plaques of obese, insulin-resistant mice depends on adiponectin-induced Irak3 expression.
por: Maarten Hulsmans, et al.
Publicado: (2013) -
TREM-1 links dyslipidemia to inflammation and lipid deposition in atherosclerosis
por: Daniel Zysset, et al.
Publicado: (2016)